Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Nyxoah SA (NASDAQ: NYXH) announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. CEO Olivier Taelman will deliver a corporate update on February 17, 2022, at 8:00 AM EST. The presentation will not be webcast, but Nyxoah will hold virtual 1x1 meetings with registered institutional investors. The company specializes in innovative treatments for Obstructive Sleep Apnea (OSA), with its lead product, Genio®, receiving CE Mark approval after the successful completion of the BLAST OSA study.
- None.
- None.
Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Mont-Saint-Guibert, Belgium – February 4, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually from February 15-17, 2022.
Olivier Taelman, Nyxoah’s Chief Executive Officer, is scheduled to present a corporate update on Thursday, February 17, 2022, at 8:00am EST. This presentation will not be webcast due to the format of the conference. The Company will also be available for virtual 1x1 meetings with institutional investors registered for the event.
Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494
Gilmartin Group
Vivian Cervantes
IR@nyxoah.com
Attachment
FAQ
What is Nyxoah presenting at the BTIG MedTech Conference?
When does Nyxoah's presentation take place during the BTIG Conference?
Will Nyxoah's presentation be available for webcast?
What innovative product does Nyxoah specialize in?
What regulatory approval has Nyxoah received for its Genio® system?
